PD-1/PD-L1 inhibitors monotherapy vs. combination therapy in elderly advanced NSCLC: a real-world study and nomogram for survival prognosis

Abstract Background Immunotherapy with PD-1/PD-L1 inhibitors has transformed advanced non-small cell lung cancer (NSCLC) treatment, yet optimal strategies for elderly patients remain uncertain. Elderly patients (≥ 65 years) exhibit immune senescence (e.g., T-cell dysfunction, chronic inflammation),...

詳細記述

書誌詳細

出版年:	BMC Pulmonary Medicine
主要な著者:	Yunye Mao, An Wang, Xiangwei Ge, Jinzhao Zhai, Yi Hu, Jinliang Wang
フォーマット:	論文
言語:	英語
出版事項:	BMC 2025-07-01
主題:	Elderly patients Advanced non-small cell lung cancer Immunotherapy Immune combination therapy
オンライン･アクセス:	https://doi.org/10.1186/s12890-025-03791-x